Xeris Biopharma Holdings Inc (NASDAQ:XERS) price on Thursday, April 10, fall -8.78% below its previous day’s close as a downside momentum from buyers pushed the stock’s value to $3.95.
A look at the stock’s price movement, the close in the last trading session was $4.33, moving within a range at $3.805 and $4.27. The beta value (5-Year monthly) was 0.885. Turning to its 52-week performance, $6.07 and $1.69 were the 52-week high and 52-week low respectively. Overall, XERS moved -13.57% over the past month.
Xeris Biopharma Holdings Inc’s market cap currently stands at around $608.06 million, with investors looking forward to this quarter’s earnings report slated for on 2025-Mar-05.
Analysts have a consensus estimate of 57.61M for the company’s revenue for the quarter, with a low and high estimate of 56.29M and 59.2M respectively. The average forecast suggests up to a 41.76% growth in sales growth compared to quarterly growth in the same period last fiscal year. Wall Street analysts have also projected the company’s year-on-year revenue to grow to 262.3M, representing a 29.17% jump on that reported in the last financial year.
Turning to the stock’s technical picture we see that short term indicators suggest on average that XERS is a 50% Buy. On the other hand, the stock is on average a 50% Buy as suggested by medium term indicators while long term indicators are putting the stock in 100% Buy category.
3 analyst(s) have given their forecast ratings for the stock on a scale of 1.00-5.00 for a strong buy to strong sell recommendation. A total of 0 analyst(s) rate the stock as a Hold, 3 recommend XERS as a Buy and 0 give it an Overweight rating. Meanwhile, 0 analyst(s) rate the stock as Underweight and 0 say it is a Sell. As such, the average rating for the stock is Buy which could provide an opportunity for investors keen on increasing their holdings of the company’s stock.
XERS’s current price about -22.78% and -9.21% off the 20-day and 50-day simple moving averages respectively. The Relative Strength Index (RSI, 14) currently prints 34.53, while 7-day volatility ratio is 12.67% and 7.55% in the 30-day chart. Further, Xeris Biopharma Holdings Inc (XERS) has a beta value of 0.95, and an average true range (ATR) of 0.37. Analysts have given the company’s stock an average 52-week price target of $5, forecast between a low of $4 and high of $6.6. Looking at the price targets, the low is -1.27% off current price level while to achieve the yearly target high, price needs to move -67.09%. Nonetheless, investors will most likely welcome a -26.58% jump to $5 which is the analysts’ median price.
If we refocus on Xeris Biopharma Holdings Inc (NASDAQ:XERS), historical trading data shows that trading volumes averaged 4.2 over the past 10 days and 2.87 million over the past 3 months. The company’s latest data on shares outstanding shows there are 149.43 million shares.
The 7.80% of Xeris Biopharma Holdings Inc’s shares are in the hands of company insiders while institutional holders own 42.82% of the company’s shares. Also important is the data on short interest which shows that short shares stood at 11.21 million on 2025-03-14, giving us a short ratio of 3.4. The data shows that as of 2025-03-14 short interest in Xeris Biopharma Holdings Inc (XERS) stood at 746.0 of shares outstanding, with shares short rising to 10.27 million registered in 2025-02-14. Current price change has pushed the stock 16.52% YTD, which shows the potential for further growth is there. It is this reason that could see investor optimism for the XERS stock continues to rise going into the next quarter.
